Abstract

Hepatitis C virus (HCV)-related cirrhosis leads to a heavy global burden of disease. Clinical risk stratification in HCV-related compensated cirrhosis remains a major challenge. Here, we aim to develop a signature comprised of immune-related genes to identify patients at high risk of progression and systematically analyze immune infiltration in HCV-related early-stage cirrhosis patients. Bioinformatics analysis was applied to identify immune-related genes and construct a prognostic signature in microarray data set. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted with the “clusterProfiler” R package. Besides, the single sample gene set enrichment analysis (ssGSEA) was used to quantify immune-related risk term abundance. The nomogram and calibrate were set up via the integration of the risk score and clinicopathological characteristics to assess the effectiveness of the prognostic signature. Finally, three genes were identified and were adopted to build an immune-related prognostic signature for HCV-related cirrhosis patients. The signature was proved to be an independent risk element for HCV-related cirrhosis patients. In addition, according to the time-dependent receiver operating characteristic (ROC) curves, nomogram, and calibration plot, the prognostic model could precisely forecast the survival rate at the first, fifth, and tenth year. Notably, functional enrichment analyses indicated that cytokine activity, chemokine activity, leukocyte migration and chemotaxis, chemokine signaling pathway and viral protein interaction with cytokine and cytokine receptor were involved in HCV-related cirrhosis progression. Moreover, ssGSEA analyses revealed fierce immune-inflammatory response mechanisms in HCV progress. Generally, our work developed a robust prognostic signature that can accurately predict the overall survival, Child-Pugh class progression, hepatic decompensation, and hepatocellular carcinoma (HCC) for HCV-related early-stage cirrhosis patients. Functional enrichment and further immune infiltration analyses systematically elucidated potential immune response mechanisms.

Highlights

  • For approximately 1.6% population with positivity for anti-hepatitis C virus (HCV) antibodies worldwide [1]

  • GSE54100 was performed using archived liver biopsy specimens from 145 patients with Hepatitis C virus (HCV)-related compensated cirrhosis who had Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; DAAs, direct-acting antivirals; Gene Expression Omnibus (GEO), gene expression omnibus; Immunology Database and Analysis Portal (ImmPort), the immunology database and analysis portal; LASSO, the least absolute shrinkage and selection operator; Gene Ontology (GO), gene ontology; Kyoto Encyclopedia of Genes and Genomes (KEGG), Kyoto encyclopedia of genes and genomes; BP, biological process; CC, cellular component; MF, molecular function; ssGSEA, the single sample gene set enrichment analysis; Protein-protein interaction networks (PPI), protein-protein interaction networks; Sustained virological response (SVR), sustained virological response; IFN-stimulated genes (ISGs), interferonstimulated genes

  • Identification and comprehensive analysis of immune genes related to prognosis in HCV-related early-stage cirrhosis patients

Read more

Summary

Introduction

For approximately 1.6% (range: 1.3–2.1%) population with positivity for anti-hepatitis C virus (HCV) antibodies worldwide [1]. Removing either spontaneously or as a result of antiviral treatment, the global viraemic prevalence (positive for HCV RNA) is estimated at 1% (range: 0.8–1.14%) individuals with HCV infection in reality [1]. 50–80% of HCV infection patients develop into chronic hepatitis C [1]. Chronic HCV infection is the primary cause of liver cirrhosis, especially in the developing world [2]. Liver cirrhosis develops from ongoing fibrosis injury and eventually leads to liver failure and HCC. Fibrosis results from the breakdown of the dynamic balance between extracellular matrix deposition and degradation in chronic diseases of the liver and other parenchymal organs [4]. Treatment for HCV with direct-acting antivirals (DAAs) regimens were associated with moderate success but were challenging to tolerate [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call